Profile
Kenneth Huttner worked as a Fellow at the National Institute of Child Health & Human Development from 1985 to 1988.
He then worked as a Medical Director at Interleukin Genetics, Inc. and as a Medical Director at CombinatoRx, Inc. from 2007 to 2009.
He worked as a Vice President-Clinical Development at Edimer Pharmaceuticals, Inc. from 2010 to 2015.
He also worked as an Executive Director-Translation Medicine at Novartis Institutes for Biomedical Research, Inc. from 2015 to 2017 and as a Vice President-Clinical Development at Bioverativ, Inc. from 2017 to 2019.
From 2019 to 2020, he worked as a Senior Vice President & Head-Clinical Development at LogicBio Therapeutics, Inc. Dr. Huttner earned a doctorate degree from Yale University.
Former positions of Kenneth Huttner
| Companies | Position | End |
|---|---|---|
| LOGICBIO THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 17/06/2020 |
| BIOVERATIV INC | Chief Tech/Sci/R&D Officer | 01/02/2019 |
Novartis Institutes for Biomedical Research, Inc.
 Novartis Institutes for Biomedical Research, Inc. Miscellaneous Commercial ServicesCommercial Services Novartis Institutes for Biomedical Research, Inc. conducts biomedical researches. It focuses in the areas of oncology, ophthalmology, diabetes, musculoskeletal disorders, neuroscience, and cardiovascular conditions, other focus areas include discovery chemistry, biologics, pathway biology, and translational medicine. The company was founded on September 10, 2002 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | 01/07/2017 |
Edimer Pharmaceuticals, Inc.
 Edimer Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Edimer Pharmaceuticals, Inc. provides biopharmaceutical products for improving the health and quality of life of families living with XLHED. It has developed EDI200 as a treatment for X-linked Hypohidrotic Ectodermal Dysplasia (XLHED), which is a rare orphan disease that causes symptoms including lack of sweat glands, poor temperature control, respiratory problems, and hair and tooth malformations. The company was founded by Pascal Schneider and Olivier Gaide in 2009 and is headquartered in Cambridge, MA. | Chief Tech/Sci/R&D Officer | 28/02/2015 |
CombinatoRx, Inc.
 CombinatoRx, Inc. Pharmaceuticals: OtherHealth Technology CombinatoRx, Inc. develops new medicines built from synergistic combinations of approved drugs. The company develops biopharmaceutical products. It conducts clinical trials and research programs. The company was founded by Alexis Borisy, Brent R. Stockwell, Michael A. Foley, Curtis T. Keith and Jacob D. Goldfield in 2000 and is headquartered in Cambridge, MA | Chief Tech/Sci/R&D Officer | 01/01/2009 |
Training of Kenneth Huttner
| Yale University | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 7 |
|---|---|
Edimer Pharmaceuticals, Inc.
Edimer Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Edimer Pharmaceuticals, Inc. provides biopharmaceutical products for improving the health and quality of life of families living with XLHED. It has developed EDI200 as a treatment for X-linked Hypohidrotic Ectodermal Dysplasia (XLHED), which is a rare orphan disease that causes symptoms including lack of sweat glands, poor temperature control, respiratory problems, and hair and tooth malformations. The company was founded by Pascal Schneider and Olivier Gaide in 2009 and is headquartered in Cambridge, MA. | Health Technology |
Interleukin Genetics, Inc.
 Interleukin Genetics, Inc. Pharmaceuticals: MajorHealth Technology Interleukin Genetics, Inc. engages in the marketing and development of proprietary genetic tests for chronic inflammatory diseases and health-related conditions focuses on metabolism and inflammation. The company was founded in 1986 and is headquartered in Waltham, MA. | Health Technology |
| National Institute of Child Health & Human Development | Government |
CombinatoRx, Inc.
CombinatoRx, Inc. Pharmaceuticals: OtherHealth Technology CombinatoRx, Inc. develops new medicines built from synergistic combinations of approved drugs. The company develops biopharmaceutical products. It conducts clinical trials and research programs. The company was founded by Alexis Borisy, Brent R. Stockwell, Michael A. Foley, Curtis T. Keith and Jacob D. Goldfield in 2000 and is headquartered in Cambridge, MA | Health Technology |
LogicBio Therapeutics, Inc.
 LogicBio Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology LogicBio Therapeutics, Inc. engages in the development of a genome editing technology platform. It focuses on the commercialization of GeneRide, which enables the site-specific integration of a therapeutic transgene without nucleases or exogenous promoters by harnessing the native process of homologous recombination. Its pipeline includes LB-001, LB-301 and LB-401. The company was founded by Mark A. Kay, Leszek Lisowski, and Adi Barzel in August 2014 and is headquartered in Lexington, MA. | Health Technology |
Novartis Institutes for Biomedical Research, Inc.
Novartis Institutes for Biomedical Research, Inc. Miscellaneous Commercial ServicesCommercial Services Novartis Institutes for Biomedical Research, Inc. conducts biomedical researches. It focuses in the areas of oncology, ophthalmology, diabetes, musculoskeletal disorders, neuroscience, and cardiovascular conditions, other focus areas include discovery chemistry, biologics, pathway biology, and translational medicine. The company was founded on September 10, 2002 and is headquartered in Cambridge, MA. | Commercial Services |
Bioverativ, Inc.
 Bioverativ, Inc. BiotechnologyHealth Technology Bioverativ, Inc. is a global biopharmaceutical company, focused on discovery, research, development and commercialization of therapies for the treatment of blood diseases including hemophilia. The company is headquartered in Cambridge, MA. | Health Technology |
- Stock Market
- Insiders
- Kenneth Huttner
